The antidepressant effect of Komagataella pastoris KM 71H in maternal separation mice model mediated by the microbiota-gut-brain axis.

Yeast depression microbiota-gut-brain axis probiotic stress

Journal

Behavioural brain research
ISSN: 1872-7549
Titre abrégé: Behav Brain Res
Pays: Netherlands
ID NLM: 8004872

Informations de publication

Date de publication:
09 Oct 2024
Historique:
received: 06 06 2024
revised: 16 09 2024
accepted: 08 10 2024
medline: 12 10 2024
pubmed: 12 10 2024
entrez: 11 10 2024
Statut: aheadofprint

Résumé

The intestinal microbiota plays a fundamental role in maintaining host health, especially during childhood, a critical period for its establishment. Early life stress can lead to shifts in gut microbiota composition, thus increasing the risk of major depressive disorder (MDD) in adulthood. The supplementation with probiotics restores intestinal permeability and the health of gut microbial communities, therefore being potential study targets for the treatment of MDD. In this sense, the yeast Komagataella pastoris was reported as a promising probiotic with antidepressant effect. Hence, the present study aims to investigate this effect in mice submitted to maternal separation (MS) 3h per day from PND2 to PND14. Adult mice and mothers were treated with K. pastoris KM71H (8log UFC.g On behavioral tests, K. pastoris KM71H treatment reduced the immobility time in TST of adult mice and increased the grooming activity in splash test of adult mice and mothers induced by MS. The probiotic treatment restored plasma corticosterone levels and glucocorticoid receptor expression in hippocampi, alongside nitrate/nitrite levels and superoxide dismutase activity in intestine, in addition to reducing reactive species levels in both structures. Moreover, it also normalized the fecal pH and water content of feces. Thus, we conclude that K. pastoris KM71H is a promising therapeutic strategy for the treatment of MDD.

Sections du résumé

BACKGROUND BACKGROUND
The intestinal microbiota plays a fundamental role in maintaining host health, especially during childhood, a critical period for its establishment. Early life stress can lead to shifts in gut microbiota composition, thus increasing the risk of major depressive disorder (MDD) in adulthood. The supplementation with probiotics restores intestinal permeability and the health of gut microbial communities, therefore being potential study targets for the treatment of MDD. In this sense, the yeast Komagataella pastoris was reported as a promising probiotic with antidepressant effect.
METHODS METHODS
Hence, the present study aims to investigate this effect in mice submitted to maternal separation (MS) 3h per day from PND2 to PND14. Adult mice and mothers were treated with K. pastoris KM71H (8log UFC.g
RESULTS RESULTS
On behavioral tests, K. pastoris KM71H treatment reduced the immobility time in TST of adult mice and increased the grooming activity in splash test of adult mice and mothers induced by MS. The probiotic treatment restored plasma corticosterone levels and glucocorticoid receptor expression in hippocampi, alongside nitrate/nitrite levels and superoxide dismutase activity in intestine, in addition to reducing reactive species levels in both structures. Moreover, it also normalized the fecal pH and water content of feces.
CONCLUSION CONCLUSIONS
Thus, we conclude that K. pastoris KM71H is a promising therapeutic strategy for the treatment of MDD.

Identifiants

pubmed: 39393682
pii: S0166-4328(24)00443-1
doi: 10.1016/j.bbr.2024.115287
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

115287

Informations de copyright

Copyright © 2024. Published by Elsevier B.V.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors have no conflict of interest in this article.

Auteurs

Paloma T Birmann (PT)

Neurobiotechnology Research Group, Postgraduate Program in Biotechnology, Technologic Development Center, Federal University of Pelotas, Pelotas, RS, Brazil.

Airton Sinott (A)

Neurobiotechnology Research Group, Postgraduate Program in Biotechnology, Technologic Development Center, Federal University of Pelotas, Pelotas, RS, Brazil.

Giuliana Petiz Zugno (GP)

Neurobiotechnology Research Group, Postgraduate Program in Biotechnology, Technologic Development Center, Federal University of Pelotas, Pelotas, RS, Brazil.

Rafael R Rodrigues (RR)

Applied Immunology Laboratory, Postgraduate Program in Biotechnology, Technological Development Center, Federal University of Pelotas, Pelotas, RS, Brazil.

Fabricio R Conceição (FR)

Applied Immunology Laboratory, Postgraduate Program in Biotechnology, Technological Development Center, Federal University of Pelotas, Pelotas, RS, Brazil.

Fernanda Severo Sabedra Sousa (FSS)

Molecular and Cellular Oncology Research Group and Functional Genomics Laboratory, Postgraduate Program in Biotechnology, Technological Development Center, Federal University of Pelotas, Pelotas, RS, Brazil.

Tiago Collares (T)

Molecular and Cellular Oncology Research Group and Functional Genomics Laboratory, Postgraduate Program in Biotechnology, Technological Development Center, Federal University of Pelotas, Pelotas, RS, Brazil.

Fabiana K Seixas (FK)

Molecular and Cellular Oncology Research Group and Functional Genomics Laboratory, Postgraduate Program in Biotechnology, Technological Development Center, Federal University of Pelotas, Pelotas, RS, Brazil.

Lucielli Savegnago (L)

Neurobiotechnology Research Group, Postgraduate Program in Biotechnology, Technologic Development Center, Federal University of Pelotas, Pelotas, RS, Brazil. Electronic address: luciellisavegnago@yahoo.com.br.

Classifications MeSH